Japan’s FFC GMP Requirements Enter Full Implementation

Japan’s strengthened rules for Foods with Function Claims (FFC) reached full implementation on 1 September 2026, when transitional arrangements for relevant GMP and labelling requirements ended. The changes followed the health damage incident involving Kobayashi Pharmaceutical’s red yeast rice-related products in 2024. The new provisions apply to food manufactured from the September date. [1]

Which products are covered?

The GMP requirement covers FFC products in the defined category of tablets, capsules and similar processed foods using natural extracts and related ingredients. It is not a blanket requirement for all foods or supplements. GMP, or Good Manufacturing Practice, sets controls across production, from receiving raw materials to deciding whether finished products can be released. [2]

The revised labelling rules also make notification information more visible: the FFC designation appears within a frame at the top of the packaging, with the notification number nearby. [1]

What changes in practice?

The Consumer Affairs Agency’s guidance addresses material specifications, batch records, testing, equipment maintenance and product-release decisions. These controls connect the quality of incoming ingredients with the finished product, rather than relying solely on a final inspection. [2]

For businesses, a practical starting point is to follow one batch through the entire process. Can the team identify the materials used, locate the relevant production and test records, and explain the release decision? Where manufacturing is outsourced, responsibilities and information-sharing arrangements deserve particular attention.

The reform makes September 2026 a significant operational milestone for the sector. Maintaining accessible records and clear responsibility supports day-to-day quality oversight. Manufacturing compliance and the scientific evidence supporting a health-related statement remain distinct matters; sound production controls do not, by themselves, establish a clinical benefit.